Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis - PubMed (original) (raw)

Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis

Jonathan A Sayer et al. Neuromolecular Med. 2005.

Abstract

Although expansion of a polyglutamine tract in the huntingtin protein is known to cause Huntington's disease (HD), there is considerable debate as to how this mutation leads to the selective neuronal loss that characterizes the disease. The observation that mutant huntingtin accumulates in neuronal nuclei has led to the hypothesis that the molecular mechanism may involve the disruption of specific nuclear activities. Recently, several nuclear interaction partners for huntingtin have been identified, including HypA, a splicing factor-like protein of unknown function. Using a yeast two-hybrid screen, we have identified the interaction of HypA with the nuclear scaffold protein NAKAP. Interaction of NAKAP with HypA is specific and occurs both in yeast and in vitro. Deletion-mapping studies indicate that binding occurs via a proline-rich domain in NAKAP with a WW domain of HypA. In cultured cells, NAKAP and HypA localize within the nucleus and copurify with the nuclear matrix. Furthermore, NAKAP associates with HypA from human brain and copurifies with huntingtin protein in brain tissue obtained from HD patients. In HD neurons, NAKAP and mutant huntingtin were colocalized to the nuclear matrix and were found to be components of nuclear aggregates. Hence, the NAKAP-HypA scaffold is a potential nuclear docking site for huntingtin protein and may contribute to the nuclear accumulation of huntingtin observed in HD.

PubMed Disclaimer

Cited by

Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington's Disease.
Podvin S, Rosenthal SB, Poon W, Wei E, Fisch KM, Hook V. Podvin S, et al. J Huntingtons Dis. 2022;11(3):243-267. doi: 10.3233/JHD-220538. J Huntingtons Dis. 2022. PMID: 35871359 Free PMC article.
Mitochondrial structural and functional dynamics in Huntington's disease.
Reddy PH, Mao P, Manczak M. Reddy PH, et al. Brain Res Rev. 2009 Jun;61(1):33-48. doi: 10.1016/j.brainresrev.2009.04.001. Epub 2009 Apr 24. Brain Res Rev. 2009. PMID: 19394359 Free PMC article. Review.
Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.
Komatsu H. Komatsu H. Front Cell Neurosci. 2021 Nov 26;15:785703. doi: 10.3389/fncel.2021.785703. eCollection 2021. Front Cell Neurosci. 2021. PMID: 34899193 Free PMC article. Review.
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
Reddy PH, Reddy TP. Reddy PH, et al. Curr Alzheimer Res. 2011 Jun;8(4):393-409. doi: 10.2174/156720511795745401. Curr Alzheimer Res. 2011. PMID: 21470101 Free PMC article. Review.
The role of A-kinase anchoring protein 95-like protein in annealing of tRNALys3 to HIV-1 RNA.
Xing L, Zhao X, Guo F, Kleiman L. Xing L, et al. Retrovirology. 2014 Jul 17;11:58. doi: 10.1186/1742-4690-11-58. Retrovirology. 2014. PMID: 25034436 Free PMC article.

References

1. Cancer Res. 1989 May 15;49(10):2525-32 - PubMed
1. Trends Mol Med. 2001 Jul;7(7):283-4 - PubMed
1. J Cell Biol. 1998 Dec 14;143(6):1457-70 - PubMed
1. Nat Genet. 2000 Sep;26(1):29-36 - PubMed
1. Science. 1997 Sep 26;277(5334):1990-3 - PubMed

Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis - PubMed (original) (raw)